<p>Assenagon Asset Management S.A. 在最近向美国证券交易委员会提交的 13F 表格中披露，在第三季度将其在 Rhythm Pharmaceuticals, Inc.（NASDAQ:RYTM - 免费报告）的持股减少了 5.8%。该公司在此期间出售了 13,870 股后，持有 224,128 股该公司的股票。截至其最近的 SEC 文件，Assenagon Asset Management S.A. 持有 Rhythm Pharmaceuticals 0.34% 的股份，价值 22,635,000 美元。</p>
<p>获取 <strong>Rhythm Pharmaceuticals</strong> 警报：</p>
<ul>
<li>7 只将推动减肥药市场的股票</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也增加或减少了对该公司的投资。Rhumbline Advisers 在第一季度将其在 Rhythm Pharmaceuticals 的持股增加了 3.6%。Rhumbline Advisers 现在持有 85,719 股该公司的股票，价值 4,541,000 美元，此前在上个季度购买了额外的 2,988 股。Siren L.L.C. 在第一季度购买了 Rhythm Pharmaceuticals 的新头寸，估计价值约为 14,701,000 美元。Voleon Capital Management LP 在第一季度购买了 Rhythm Pharmaceuticals 的新头寸，估计价值约为 732,000 美元。Intech Investment Management LLC 在第一季度将其在 Rhythm Pharmaceuticals 的持股增加了 20.7%。Intech Investment Management LLC 现在持有 33,893 股该公司的股票，价值 1,795,000 美元，此前在此期间购买了额外的 5,801 股。最后，Harbor Capital Advisors Inc. 在第二季度将其在 Rhythm Pharmaceuticals 的头寸增加了 12.0%。Harbor Capital Advisors Inc. 现在持有 86,546 股该公司的股票，价值 5,469,000 美元，此前在上个季度收购了额外的 9,249 股。</p>
<h2>Rhythm Pharmaceuticals 价格表现</h2>
<p>RYTM 股票在周五开盘价为 112.14 美元。Rhythm Pharmaceuticals, Inc. 的 1 年最低价为 45.90 美元，1 年最高价为 122.20 美元。该公司的 50 日移动平均价格为 106.54 美元，200 日移动平均价格为 93.80 美元。该股票的市值为 74.8 亿美元，市盈率为 -36.17，贝塔值为 1.96。</p>
<ul>
<li>2 家生物科技公司有前景的减肥药即将推出</li>
</ul>
<p>Rhythm Pharmaceuticals（NASDAQ:RYTM - 获取免费报告）最近于 11 月 4 日发布了季度财报。该公司报告季度每股收益为（$0.82），低于市场共识预期的（$0.72）$0.10。Rhythm Pharmaceuticals 的股本回报率为 -433.21%，净利润率为 -110.32%。该公司在本季度的收入为 5,130 万美元，而市场共识预期为 5,071 万美元。整体来看，分析师预计 Rhythm Pharmaceuticals, Inc. 本年度每股收益将为 -4.32。</p>
<h2>内部买卖</h2>
<p>在其他消息中，内部人士 Pamela J. Cramer 于 12 月 11 日星期四出售了 3,350 股 Rhythm Pharmaceuticals 股票。该股票以平均价格 111.00 美元出售，总价值为 371,850.00 美元。出售完成后，内部人士直接持有该公司 20,814 股，价值 2,310,354 美元。此次交易使其持股减少了 13.86%。该出售在向 SEC 的法律文件中披露，文件可通过此链接获取。此外，内部人士 Joseph Shulman 于 10 月 30 日星期四出售了 9,748 股该股票。该股票以平均价格 115.24 美元出售，总交易额为 1,123,359.52 美元。交易完成后，内部人士持有该公司 8,509 股，价值约 980,577.16 美元。此次交易使其持股减少了 53.39%。该出售的披露在 SEC 文件中可获得。内部人士在上个季度出售了价值 3,436,340 美元的 30,350 股公司股票。公司内部人士持有该公司 6.10% 的股份。</p>
<h2>分析师评级变动</h2>
<p>一些研究公司最近对 RYTM 发表了评论。Guggenheim 将 Rhythm Pharmaceuticals 的目标价格从 120.00 美元上调至 140.00 美元，并在周三的研究报告中给予该公司 “买入” 评级。Cowen 在 12 月 11 日星期四的研究报告中重申了对 Rhythm Pharmaceuticals 股票的 “买入” 评级。瑞银集团在周三的研究报告中重申了对 Rhythm Pharmaceuticals 股票的 “买入” 评级。JMP Securities 在 9 月 25 日星期四的研究报告中将 Rhythm Pharmaceuticals 股票的目标价格从 135.00 美元上调至 142.00 美元，并给予该股票 “市场表现优于大盘” 评级。最后，Oppenheimer 在 11 月 5 日星期三的研究报告中将 Rhythm Pharmaceuticals 股票的评级从 “表现优于大盘” 下调至 “市场表现”。一位研究分析师给予该股票 “强烈买入” 评级，十六位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价格为 125.60 美元。</p>
<p><strong>阅读我们关于 RYTM 的最新报告</strong></p>
<h2>Rhythm Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Rhythm Pharmaceuticals, Inc. 是一家临床阶段的生物技术公司，致力于开发针对罕见遗传性肥胖和代谢功能障碍的靶向疗法。该公司的研究重点是黑色素皮质素-4 受体（MC4R）通路，该通路在调节食欲、能量消耗和体重方面发挥着核心作用。利用专有的肽技术，Rhythm 旨在为具有特定基因变异的患者提供精准治疗，这些变异会干扰正常的体重调节。</p>
<p>该公司的主要研究产品 setmelanotide 是一种选择性 MC4R 激动剂，旨在恢复在 POMC、LEPR 和 PCSK1 等基因缺陷患者中的信号传导。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，胜过 Rhythm Pharmaceuticals</li>
<li>股息支付比率计算器</li>
<li>耐克盈利超预期，但在中国市场面临挑战并遭遇关税</li>
<li>上海证券交易所综合指数是什么？</li>
<li>人工智能热潮是泡沫吗？这两只股息股票表示不是</li>
<li>现在值得购买的三只沃伦·巴菲特股票</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Rhythm Pharmaceuticals 吗？</h2>
<p>在考虑 Rhythm Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Rhythm Pharmaceuticals 并不在名单上。</p>
<p>虽然 Rhythm Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RYTM

<p>Assenagon Asset Management S.A. 将其在 Rhythm Pharmaceuticals 的持股比例减少了 5.8%，出售了 13,870 股。Rhythm Pharmaceuticals 的股票开盘价为 112.14 美元，1 年最低价为 45.90 美元，最高价为 122.20 美元。分析师的评级不一，Guggenheim 将目标价上调至 140 美元，而 Oppenheimer 则下调至 “市场表现”。内部人士在上个季度出售了价值 3,436,340 美元的 30,350 股</p>

<p>Assenagon Asset Management S.A. cut its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 5.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 224,128 shares of the company's stock after selling 13,870 shares during the period. Assenagon Asset Management S.A. owned 0.34% of Rhythm Pharmaceuticals worth $22,635,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Assenagon Asset Management S.A. 在最近向美国证券交易委员会提交的 13F 表格中披露，在第三季度将其在 Rhythm Pharmaceuticals, Inc.（NASDAQ:RYTM - 免费报告）的持股减少了 5.8%。该公司在此期间出售了 13,870 股后，持有 224,128 股该公司的股票。截至其最近的 SEC 文件，Assenagon Asset Management S.A. 持有 Rhythm Pharmaceuticals 0.34% 的股份，价值 22,635,000 美元。</p>
</div><p>Get <strong>Rhythm Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rhythm Pharmaceuticals</strong> 警报：</p>
</div><ul>
<li>7 Stocks That Will Drive the Weight Loss Drugs Market</li>
</ul>
<div class="lb-trans"><ul>
<li>7 只将推动减肥药市场的股票</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Rhumbline Advisers raised its holdings in Rhythm Pharmaceuticals by 3.6% in the 1st quarter. Rhumbline Advisers now owns 85,719 shares of the company's stock worth $4,541,000 after purchasing an additional 2,988 shares in the last quarter. Siren L.L.C. purchased a new position in shares of Rhythm Pharmaceuticals during the first quarter valued at about $14,701,000. Voleon Capital Management LP purchased a new position in shares of Rhythm Pharmaceuticals during the first quarter valued at about $732,000. Intech Investment Management LLC lifted its holdings in Rhythm Pharmaceuticals by 20.7% in the first quarter. Intech Investment Management LLC now owns 33,893 shares of the company's stock worth $1,795,000 after buying an additional 5,801 shares during the period. Finally, Harbor Capital Advisors Inc. boosted its position in Rhythm Pharmaceuticals by 12.0% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 86,546 shares of the company's stock valued at $5,469,000 after acquiring an additional 9,249 shares in the last quarter.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也增加或减少了对该公司的投资。Rhumbline Advisers 在第一季度将其在 Rhythm Pharmaceuticals 的持股增加了 3.6%。Rhumbline Advisers 现在持有 85,719 股该公司的股票，价值 4,541,000 美元，此前在上个季度购买了额外的 2,988 股。Siren L.L.C. 在第一季度购买了 Rhythm Pharmaceuticals 的新头寸，估计价值约为 14,701,000 美元。Voleon Capital Management LP 在第一季度购买了 Rhythm Pharmaceuticals 的新头寸，估计价值约为 732,000 美元。Intech Investment Management LLC 在第一季度将其在 Rhythm Pharmaceuticals 的持股增加了 20.7%。Intech Investment Management LLC 现在持有 33,893 股该公司的股票，价值 1,795,000 美元，此前在此期间购买了额外的 5,801 股。最后，Harbor Capital Advisors Inc. 在第二季度将其在 Rhythm Pharmaceuticals 的头寸增加了 12.0%。Harbor Capital Advisors Inc. 现在持有 86,546 股该公司的股票，价值 5,469,000 美元，此前在上个季度收购了额外的 9,249 股。</p>
</div><h2>Rhythm Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 价格表现</h2>
</div><p>RYTM stock opened at $112.14 on Friday. Rhythm Pharmaceuticals, Inc. has a 1-year low of $45.90 and a 1-year high of $122.20. The business has a fifty day moving average price of $106.54 and a 200-day moving average price of $93.80. The stock has a market capitalization of $7.48 billion, a P/E ratio of -36.17 and a beta of 1.96.</p>
<div class="lb-trans"><p>RYTM 股票在周五开盘价为 112.14 美元。Rhythm Pharmaceuticals, Inc. 的 1 年最低价为 45.90 美元，1 年最高价为 122.20 美元。该公司的 50 日移动平均价格为 106.54 美元，200 日移动平均价格为 93.80 美元。该股票的市值为 74.8 亿美元，市盈率为 -36.17，贝塔值为 1.96。</p>
</div><ul>
<li>2 biotechs with promising weight-loss drugs coming</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家生物科技公司有前景的减肥药即将推出</li>
</ul>
</div><p>Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.10). Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%.The business had revenue of $51.30 million during the quarter, compared to the consensus estimate of $50.71 million. As a group, analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals（NASDAQ:RYTM - 获取免费报告）最近于 11 月 4 日发布了季度财报。该公司报告季度每股收益为（$0.82），低于市场共识预期的（$0.72）$0.10。Rhythm Pharmaceuticals 的股本回报率为 -433.21%，净利润率为 -110.32%。该公司在本季度的收入为 5,130 万美元，而市场共识预期为 5,071 万美元。整体来看，分析师预计 Rhythm Pharmaceuticals, Inc. 本年度每股收益将为 -4.32。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, insider Pamela J. Cramer sold 3,350 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the sale, the insider directly owned 20,814 shares in the company, valued at $2,310,354. The trade was a 13.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Joseph Shulman sold 9,748 shares of the stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $115.24, for a total transaction of $1,123,359.52. Following the transaction, the insider owned 8,509 shares in the company, valued at approximately $980,577.16. This trade represents a 53.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 30,350 shares of company stock valued at $3,436,340 over the last quarter. Company insiders own 6.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，内部人士 Pamela J. Cramer 于 12 月 11 日星期四出售了 3,350 股 Rhythm Pharmaceuticals 股票。该股票以平均价格 111.00 美元出售，总价值为 371,850.00 美元。出售完成后，内部人士直接持有该公司 20,814 股，价值 2,310,354 美元。此次交易使其持股减少了 13.86%。该出售在向 SEC 的法律文件中披露，文件可通过此链接获取。此外，内部人士 Joseph Shulman 于 10 月 30 日星期四出售了 9,748 股该股票。该股票以平均价格 115.24 美元出售，总交易额为 1,123,359.52 美元。交易完成后，内部人士持有该公司 8,509 股，价值约 980,577.16 美元。此次交易使其持股减少了 53.39%。该出售的披露在 SEC 文件中可获得。内部人士在上个季度出售了价值 3,436,340 美元的 30,350 股公司股票。公司内部人士持有该公司 6.10% 的股份。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research firms have recently commented on RYTM. Guggenheim raised their target price on Rhythm Pharmaceuticals from $120.00 to $140.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday. Cowen reissued a &#34;buy&#34; rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, December 11th. UBS Group reaffirmed a &#34;buy&#34; rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday. JMP Securities increased their price target on shares of Rhythm Pharmaceuticals from $135.00 to $142.00 and gave the stock a &#34;market outperform&#34; rating in a research note on Thursday, September 25th. Finally, Oppenheimer cut shares of Rhythm Pharmaceuticals from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $125.60.</p>
<div class="lb-trans"><p>一些研究公司最近对 RYTM 发表了评论。Guggenheim 将 Rhythm Pharmaceuticals 的目标价格从 120.00 美元上调至 140.00 美元，并在周三的研究报告中给予该公司 “买入” 评级。Cowen 在 12 月 11 日星期四的研究报告中重申了对 Rhythm Pharmaceuticals 股票的 “买入” 评级。瑞银集团在周三的研究报告中重申了对 Rhythm Pharmaceuticals 股票的 “买入” 评级。JMP Securities 在 9 月 25 日星期四的研究报告中将 Rhythm Pharmaceuticals 股票的目标价格从 135.00 美元上调至 142.00 美元，并给予该股票 “市场表现优于大盘” 评级。最后，Oppenheimer 在 11 月 5 日星期三的研究报告中将 Rhythm Pharmaceuticals 股票的评级从 “表现优于大盘” 下调至 “市场表现”。一位研究分析师给予该股票 “强烈买入” 评级，十六位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价格为 125.60 美元。</p>
</div><p><strong>Read Our Latest Report on RYTM</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 RYTM 的最新报告</strong></p>
</div><h2>Rhythm Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company's research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals, Inc. 是一家临床阶段的生物技术公司，致力于开发针对罕见遗传性肥胖和代谢功能障碍的靶向疗法。该公司的研究重点是黑色素皮质素-4 受体（MC4R）通路，该通路在调节食欲、能量消耗和体重方面发挥着核心作用。利用专有的肽技术，Rhythm 旨在为具有特定基因变异的患者提供精准治疗，这些变异会干扰正常的体重调节。</p>
</div><p>The company's lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.</p>
<div class="lb-trans"><p>该公司的主要研究产品 setmelanotide 是一种选择性 MC4R 激动剂，旨在恢复在 POMC、LEPR 和 PCSK1 等基因缺陷患者中的信号传导。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Rhythm Pharmaceuticals</li>
<li>Dividend Payout Ratio Calculator</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Rhythm Pharmaceuticals</li>
<li>股息支付比率计算器</li>
<li>耐克盈利超预期，但在中国市场面临挑战并遭遇关税</li>
<li>上海证券交易所综合指数是什么？</li>
<li>人工智能热潮是泡沫吗？这两只股息股票表示不是</li>
<li>现在值得购买的三只沃伦·巴菲特股票</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RYTM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Rhythm Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Rhythm Pharmaceuticals 吗？</h2>
</div><p>Before you consider Rhythm Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Rhythm Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Rhythm Pharmaceuticals 并不在名单上。</p>
</div><p>While Rhythm Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rhythm Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Assenagon Asset Management S.A. 出售了 13,870 股 Rhythm Pharmaceuticals, Inc.（股票代码：RYTM）的股票